<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03463031</url>
  </required_header>
  <id_info>
    <org_study_id>GSP 301-305</org_study_id>
    <nct_id>NCT03463031</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of GSP 301 Nasal Spray in Children (Aged 6 to Under 12 Years) With Seasonal Allergic Rhinitis (SAR)</brief_title>
  <acronym>GSP 301-305</acronym>
  <official_title>A Double-Blind, Randomized, Parallel-Group Study to Evaluate the Efficacy, Safety and Tolerability of Fixed Dose Combination GSP 301 Nasal Spray Compared With Placebo Nasal Spray in Pediatric Subjects (Aged 6 to Under 12 Years) With Seasonal Allergic Rhinitis (SAR)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Glenmark Specialty S.A.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Glenmark Specialty S.A.</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Study to evaluate the efficacy, safety and tolerability of GSP 301 nasal spray (NS) compared
      with placebo NS in pediatric subjects (aged 6 to under 12 years) with Seasonal Allergic
      Rhinitis (SAR).
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 16, 2018</start_date>
  <completion_date type="Anticipated">July 31, 2018</completion_date>
  <primary_completion_date type="Anticipated">July 31, 2018</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline in average AM and PM subject-reported 12-hour reflective Total Nasal Symptom Score (rTNSS)</measure>
    <time_frame>14 Days</time_frame>
    <description>The reflective Total Nasal Symptom Score (rTNSS) will be calculated as the sum of 12-hour reflective scoring of the severity of four nasal symptoms (nasal congestion, rhinorrhea, nasal itching, sneezing). Subjects will respond on a 4-point severity scale with scores ranging from 0 (no signs/symptoms evident) to 3 (severe signs/symptoms that is hard to tolerate).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in average AM and PM subject-reported 12-hour instantaneous Total Nasal Symptom Score (iTNSS)</measure>
    <time_frame>14 days</time_frame>
    <description>Instantaneous Total Nasal Symptom Score (iTNSS) will be calculated as the sum of instantaneous scoring of the severity of four nasal symptoms (nasal congestion, rhinorrhea, nasal itching, sneezing). Subjects will respond on a 4-point severity scale with scores ranging from 0 (no signs/symptoms evident) to 3 (severe signs/symptoms that is hard to tolerate).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in the overall Pediatric Rhinoconjunctivitis Quality of Life Questionnaire (PRQLQ) score</measure>
    <time_frame>Day 15</time_frame>
    <description>The PRQLQ has total 23 questions in five domains (nose symptoms, eye symptoms, practical problems, activity limitation and other symptoms) related to how much a subject was bothered with symptoms. Subjects will respond on a 7-point scale with score ranging from 0 (not bothered) to 6 (extremely bothered). Overall PRQLQ score is the mean of all 23 subject-reported responses.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in average AM and PM subject-reported 12-hour reflective Total Ocular Symptom Score (rTOSS)</measure>
    <time_frame>14 Days</time_frame>
    <description>The reflective Total Ocular Symptom Score (rTOSS) will be calculated as the total sum of 3 ocular symptoms (itching/burning eyes, tearing/watering eyes, and redness of eyes). Subjects will respond on a 4-point severity scale with scores ranging from 0 (no signs/symptoms evident) to 3 (severe signs/symptoms that is hard to tolerate).</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">450</enrollment>
  <condition>Seasonal Allergic Rhinitis (SAR)</condition>
  <arm_group>
    <arm_group_label>GSP 301 NS</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Fixed dose combination of olopatadine hydrochloride 665 μg and mometasone furoate 25 μg NS</description>
  </arm_group>
  <arm_group>
    <arm_group_label>GSP 301 Placebo NS</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>GSP 301 Placebo nasal spray</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GSP 301 NS</intervention_name>
    <description>1 spray in each nostril twice daily for 14 days</description>
    <arm_group_label>GSP 301 NS</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GSP 301 Placebo NS</intervention_name>
    <description>1 spray in each nostril twice daily for 14 days</description>
    <arm_group_label>GSP 301 Placebo NS</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Male and female subjects aged ≥6 to &lt;12 years

          2. Clinical history of SAR (at least 2 years) with exacerbations during the study season
             for the relevant seasonal allergen (e.g., tree/grass pollen)

          3. Demonstrated sensitivity to at least 1 seasonal allergen through positive skin prick
             test within 12 months prior to screening

          4. A 12-hour rTNSS value ≥6 out of a possible 12 for the morning assessment at screening

          5. Signed informed consent/assent form (subject and parent/caregiver/legal guardian)

        Exclusion Criteria:

          1. Females of childbearing potential or pregnant

          2. Plans to travel outside the known pollen area for the investigational site for 24
             hours or longer during the last 7 days of the run-in period.

          3. History of anaphylaxis and/or other severe local reaction(s) to skin testing

          4. History and evidence of acute or significant chronic sinusitis or chronic purulent
             post nasal drip

          5. Subjects with an active pulmonary disorder or infection.

          6. Subjects with posterior subcapsular cataracts or glaucoma
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Years</minimum_age>
    <maximum_age>11 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sudeesh Tantry, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Glenmark Pharmaceuticals Ltd.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Eileen Wolff, BS</last_name>
    <phone>1-201-684-8000</phone>
    <email>clinicaltrialsdisclosuredesk@glenmarkpharma.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Glenmark Investigational Site 18</name>
      <address>
        <city>Mission Viejo</city>
        <state>California</state>
        <zip>19406</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>William Berger, MD</last_name>
      <email>tlarson@allergee.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Glenmark Investigational Site 32</name>
      <address>
        <city>Ontario</city>
        <state>California</state>
        <zip>910762</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Rosario Retino, MD</last_name>
      <email>fharder@ocri.us</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Glenmark Investigational Site 30</name>
      <address>
        <city>Paramount</city>
        <state>California</state>
        <zip>90723</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Liberation De Leon, MD</last_name>
      <email>clinresch@aol.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Glenmark Investigational Site 17</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92108</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bruce Prenner, MD</last_name>
      <email>Prenner@aaamg.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Glenmark Investigational Site 21</name>
      <address>
        <city>Colorado Springs</city>
        <state>Colorado</state>
        <zip>80907</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>William Storms, MD</last_name>
      <email>wstorms@stormsallergy.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Glenmark Investigational Site 13</name>
      <address>
        <city>Marietta</city>
        <state>Georgia</state>
        <zip>30060</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Stanley Fineman, MD</last_name>
      <email>sfineman@atlantaallergy.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Glenmark Investigational Site 26</name>
      <address>
        <city>Savannah</city>
        <state>Georgia</state>
        <zip>31312</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Brad Goodman, MD</last_name>
      <email>bgoodman@coastalallergy.net</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Glenmark Investigational Site 28</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stephen Pollard, MD</last_name>
      <email>spollard@familyallergy.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Glenmark Investigational Site 14</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21236-5992</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jonathan Matz, MD</last_name>
      <email>jonathanmatz@yahoo.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Glenmark Investigational Site 19</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20814-2672</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gordon Raphael, MD</last_name>
      <email>raphael4@comcast.net</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Glenmark Investigational Site 25</name>
      <address>
        <city>Ypsilanti</city>
        <state>Michigan</state>
        <zip>48197</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jeffrey Leflein, MD</last_name>
      <email>jleflein@annarborallergy.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Glenmark Investigational Site 12</name>
      <address>
        <city>Columbia</city>
        <state>Missouri</state>
        <zip>65203</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mark Vandewalker, MD</last_name>
      <email>MLVstudy@ozark.aero</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Glenmark Investigational Site 10</name>
      <address>
        <city>Rolla</city>
        <state>Missouri</state>
        <zip>65401</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sanchayita Tripathy, MD</last_name>
      <email>SITstudy@ozark.aero</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Glenmark Investigational Site 27</name>
      <address>
        <city>Warrensburg</city>
        <state>Missouri</state>
        <zip>64093</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lawrence Landwehr, MD</last_name>
      <email>LPLstudy@ozark.aero</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Glenmark Investigational Site 15</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68114</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Michael Dunn, MD</last_name>
      <email>dunn@qcromaha.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Glenmark Investigational Site 3</name>
      <address>
        <city>High Point</city>
        <state>North Carolina</state>
        <zip>27262-4320</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jose Bardelas, MD</last_name>
      <email>j.bardelas@northstate.net</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Glenmark Investigational Site 8</name>
      <address>
        <city>Raleigh</city>
        <state>North Carolina</state>
        <zip>27607</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Karen Dunn, MD</last_name>
      <email>karend@nccr.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Glenmark Investigational Site 11</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45231</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>David Bernstein, MD</last_name>
      <email>Kmurphy@bernsteincrc.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Glenmark Investigational Site 29</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45242</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gregory Gottschlich, MD</last_name>
      <email>ggottschlich@nhcr.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Glenmark Investigational Site 2</name>
      <address>
        <city>Edmond</city>
        <state>Oklahoma</state>
        <zip>73034</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jeremy Cole, MD</last_name>
      <email>flee@okclinicalresearch.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Glenmark Investigational Site 33</name>
      <address>
        <city>Tulsa</city>
        <state>Oklahoma</state>
        <zip>74136</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Iftikhar Hussain, MD</last_name>
      <email>iftikhar.hussain@aaicenter.net</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Glenmark Investigational Site 4</name>
      <address>
        <city>Medford</city>
        <state>Oregon</state>
        <zip>97504-9741</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Edward Kerwin, MD</last_name>
      <email>ekerwin@criresearch.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Glenmark Investigational Site 6</name>
      <address>
        <city>Spartanburg</city>
        <state>South Carolina</state>
        <zip>29303</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Charles Fogarty</last_name>
      <email>cfogarty@medresearch.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Glenmark Investigational Site 5</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78759</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Thomas Falvey, MD</last_name>
      <email>tfalvey@scrtrials.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Glenmark Investigational Site 24</name>
      <address>
        <city>Kerrville</city>
        <state>Texas</state>
        <zip>78028-6071</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dale Mohar, MD</last_name>
      <email>dmohar@kerrresearch.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Glenmark Investigational Site 1</name>
      <address>
        <city>New Braunfels</city>
        <state>Texas</state>
        <zip>78130</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Frank Hample, MD</last_name>
      <email>fchampel@aol.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Glenmark Investigational Site 7</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229-3749</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Charles Andrews, MD</last_name>
      <email>bandrews@dxrg.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Glenmark Investigational Site 9</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Robert Jacobs, MD</last_name>
      <email>robert.jacobs7025@sbcglobal.net</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Glenmark Investigational Site 20</name>
      <address>
        <city>Waco</city>
        <state>Texas</state>
        <zip>76712</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Niran Amar, MD</last_name>
      <email>namar@aactx.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Glenmark Investigational Site 31</name>
      <address>
        <city>Waco</city>
        <state>Texas</state>
        <zip>76712</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pramila Daftary, MD</last_name>
      <email>pkdoffice@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Glenmark Investigational Site 22</name>
      <address>
        <city>Draper</city>
        <state>Utah</state>
        <zip>84020</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Duane Harris, MD</last_name>
      <email>dharris@icrtrials.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Glenmark Investigational Site 23</name>
      <address>
        <city>Greenfield</city>
        <state>Wisconsin</state>
        <zip>53288</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Gary Steven, MD</last_name>
      <email>gsteven@myaasc.com</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 5, 2018</study_first_submitted>
  <study_first_submitted_qc>March 9, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">March 13, 2018</study_first_posted>
  <last_update_submitted>May 25, 2018</last_update_submitted>
  <last_update_submitted_qc>May 25, 2018</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 28, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>GSP 301 nasal spray for the treatment of Seasonal Allergic Rhinitis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rhinitis</mesh_term>
    <mesh_term>Rhinitis, Allergic</mesh_term>
    <mesh_term>Rhinitis, Allergic, Seasonal</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

